• Multiple endocrine neoplasia type 1 (MEN1) is an inherited condition that leads to growth of mainly benign (non-cancerous) tumours of the endocrine glands.
• The features of MEN1 usually present in adulthood and manifestation before teenage years is very rare.
• The most common presenting feature of MEN1 is hyperparathyroidism with raised calcium levels owing to growth of the parathyroid glands.
• MEN1 is an autosomal dominant condition caused by alterations in the MEN1 gene.
• Individuals with an alteration in the MEN1 gene should undergo regular surveillance to screen for MEN1-associated tumours and their hormonal effects.
• Early diagnosis, treatment and management improves outcome and quality of life for those affected.
• The prevalence of MEN1 has been estimated at 1 in 10,000 of the population.
Clinical features
• The features of MEN1 vary depending on the types of tumours that occur and the hormones they produce. The three most common tumours to occur in MEN1 are:
Parathyroid tumours
• Onset of hyperparathyroidism is usually after the age of 20. Over 90% of patients with MEN1 will develop hyperparathyroidism by the age of 50.
• Growths in the parathyroid gland result in hyperparathyroidism (raised PTH levels) and hypercalcaemia.
• Hypercalcaemia can lead a wide range of symptoms including thirst, lethargy, aches and pains, muscle weakness and constipation.
• If left untreated,the long term effects of hypercalcaemia can include osteoporosis and renal stones.
Pancreatic neuroendocrine tumours
• May occur in up to 75% of MEN1 patients.
• The symptoms will depend on the type of tumour and the hormones which are produced.
• Gastronomas are the most common neuroendocrine tumours in MEN1, with excess gastric production leading to acid reflux, indigestion and gastric/duodenal ulcers.
• Insulinomas producing excess insulin cause symptoms of hypoglycaemia.
• About 10% of patients with MEN1 may experience more than one type of pancreatic tumour.
• Some (pancreatic) neuroendocrine tumours have the potential to become malignant if left untreated and metastasise.
Pituitary tumours (pituitary adenoma)
• Around 30% of MEN1 patients will develop a pituitary tumour.
• The effect of the tumour will depend on which hormones are produced.
• Tumours may secrete prolactin (causing infertility issues), growth hormone (affecting the size of the jaw bone and hands and feet) and ACTH (causing the adrenal gland to overproduce cortisol).
• Some tumours can be non-functioning (do not produce hormones) and some may affect vision through compression of the optic nerve.
Diagnosis
A clinical diagnosis of MEN1 can be made when:
• a patient develops two or more MEN1 associated tumours; or
• a patient with a family history of MEN1 develops one MEN1 associated tumour.
Genetic basis
• MEN1 is caused by alterations in the MEN1 gene, which are inherited in an autosomal dominant manner.
• An affected individual has one usual and one altered copy of the MEN1 gene. Each time an affected person has a child they will pass on either the usual or the altered copy of the gene. Children of an affected individual therefore have a 1-in-2 (50%) chance of inheriting the gene alteration.
• A proportion of families with MEN1 will not have identifiable changes in the MEN1 gene.
Clinical management
• Affected patients should be managed in a specialised endocrine clinic.
• Regular surveillance is needed to screen for MEN1 associated tumours and their hormonal effects.
• Screening may include a medical review for assessment of symptoms, biochemical screening to check the level of PTH /calcium and other hormones, imaging of the pituitary/pancreatic gland.
• Parathyroid tumours can be treated by surgical removal of the parathyroid glands. The tumours usually reoccur, so surgeons often remove 3 1/2 glands with implantation of the remaining portion.
• Treatment of pituitary tumours may require medical treatment or surgery, and in some cases radiotherapy.
• The treatment of pancreatic tumours will depend on the size, type number and location of the tumours.
• Proton pump inhibitors (inhibit stomach acid production) are used for medical treatment of gastrinomas.
• Treatment for insulinomas may involve surgical removal of a tumour (over 2cms) or partial/complete removal of the pancreas.
• Tumours may metastasise to the liver and may be treated by chemotherapy, newer targeted therapies (eg tyrosine kinase inhibitors) or radio ablation.
• Patients should be offered genetic counselling and testing of the MEN1 gene.
Genetic testing
Indications for genetic testing and genetic counselling include:
• diagnostic testing in patients with two or more MEN1 associated tumours;
• consideration of testing in young patients (< 40) with isolated parathyroid hyperplasia;
• diagnostic testing in a symptomatic blood relative;
• predictive/presymptomatic testing for first degree relatives of an affected individual; and
• affected individuals who are considering prenatal diagnosis.
Genetic testing is available in the UK and usually provided through specialist clinics or regional genetic centres. 
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